solid tumorsmelanomarelapsed/refractory hematologic malignanciesCAR-T cell therapyId3-CARId3CAR-T therapycheckpoint blockade immunotherapy
…e remain key challenges that limit the therapeutic potential in solid tumors. T cells are hardwired to pursue a natural path of differentiat…